Form 4: Coherus Oncology Director Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Jill O'Donnell-Tormey was granted 30,000 restricted stock units and 60,000 stock options by Coherus Oncology.
Summary
- Director Jill O'Donnell-Tormey acquired 30,000 restricted stock units (RSUs) on June 5, 2026.
- The director was also granted 60,000 stock options with an exercise price of $1.45 per share.
- Both the RSUs and stock options are subject to a one-year vesting period, contingent on continued service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Retention of key leadership personnel through long-term vesting schedules.
Negatives
- Potential for future shareholder dilution upon the exercise of options and vesting of RSUs.
Risks
- Vesting is contingent upon the director's continued service relationship with the issuer.
- Market price volatility could impact the future value of the granted equity.
Future Outlook
The equity grants are subject to a one-year vesting period ending June 3, 2027, requiring the director's continued service.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure long-term alignment between board members and shareholders.
Comparison to Industry Standards
- The use of RSUs and stock options as part of director compensation is consistent with standard practices for mid-cap biotechnology firms.
- One-year cliff vesting is a common retention mechanism for board members in the life sciences industry.
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of options and vesting of RSUs.
Next Steps
- Vesting of RSUs and stock options on June 3, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/05/2026 | Date of the equity grant transaction. |
| 06/03/2027 | Vesting date for both RSUs and stock options. |
| 06/05/2036 | Expiration date for the stock options. |
Keywords
Coherus Oncology, CHRS, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.